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ABSTRACT
Background  and  the  purpose  of  the  study:  Non-steroidal  anti-inflammatory  drug-activated 
gene-1 (NAG-1) is involved in inflammation, apoptosis/survival and tumorigenesis as well as 
resistance to chemotherapy. NAG-1 protein is synthesized as pro-peptide, cleaved and secreted 
as mature protein. Regulation of  NAG-1 is not completely discovered and increased level of 
NAG-1 has been reported in many cancers. The expression of NAG-1 in cancer cells could 
affect the progression of tumor growth. In addition  the secretion of full length and mature forms 
of NAG-1 can influence cell proliferation in other cells. In this study the role of full length and 
mature forms of  NAG-1 on viability of HT-1080 and MCF-7 cells were evaluated, and the 
cytotoxicity of celecoxib, indomethacin, tamoxifen and doxorubicin in HT1080 cells stably 
expressing NAG-1 were also tested.  
Methods: Full length and mature NAG-1 was cloned from cDNA library of HCT116 cells 
and stably transfected in HT1080 cells. Cells were treated with different concentrations of 
indomethacin, celecoxib, tamoxifen and doxorubicin and viability was assessed by MTT assay. 
The effect of conditioned medium of NAG-1 expressing cells on proliferation of MCF-7 and 
HT1080 cells were also tested.
Results: The growth curves of HT1080 cells expressing full length and mature NAG-1 were not 
different. The viability of HT1080 cells expressing NAG-1 in the presence of indomethacin, 
doxorubicin and tamoxifen compared to untransfected cells was higher. The proliferation of 
HT1080 and MCF-7 cells were inhibited by conditioned medium of NAG-1 expressing cells in 
24 and 48 hrs.
Major conclusion: NAG-1 expression enhances drug resistance to tamoxifen, indomethacin 
and doxorubicin in HT1080. In addition, condition medium of NAG-1 expression cells inhibits 
proliferation in MCF-7 and HT1080 cells. Thus, NAG-1 expression can induce drug resistance 
in NAG-1 expressing cells and inhibition of viability in non expressing cells. Thus, NAG-1 is 
suggested as a marker for effective cancer chemotherapy and tumor progression.
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INTRODUCTION
Non-steroidal  anti-inflammatory  drug-activated 
gene-1 (NAG-1), (also known as MIC-1, GDF-15, 
PTGFβ and PLAB) is a distinct member of TGFβ 
super family which is involved in different cellular 
processes like inflammation, apoptosis/survival and 
tumorigenesis as well as resistance to chemotherapy 
and radiotherapy (1, 2). NAG-1 protein is synthesized 
as a 308-amino acid pro-peptide. The mature form is 
secreted as a 30-kDa dimeric  protein after furin like 
cleavage at the RXXR site and formation of many 
disulfide  bonds  between  cysteine  residues  in  the 
endoplasmic reticulum (2). It has been shown that 
NAG-1 expression increased during inflammation, 
tissue  injury  and  malignancy.  Increased  NAG-1 
expression is a common feature of many cancers, 
including  breast,  colon,  pancreas  and  prostate 
cancers, suggesting NAG-1 as a tumor biomarker. 
Regulation  and  expression  of  NAG-1  is  not 
completely discovered but it is known that NAG-1 
is one of target genes of p53 activating pathways and 
its expression is induced either through p53 and/or 
EGR-1 related pathways (3-6).
The  function  and  signaling  pathway  of  NAG-1 
in  cancer  progression  and  treatment  still  remain 
unclear. Although there are in vitro studies suggesting 
anti-proliferative  and  pro-apoptotic  functions  of 
NAG-1  in  cancers  of  colon,  breast  and  prostate 
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subcloned into pCDNA3.1 in HindIII and XhoI sites. 
The generated plasmids were analyzed by agarose 
gel electrophoresis and the sequences were verified 
by DNA sequencing.
Stable transfection
HT1080 cells were plated at 500 × 103  cells/well 
in 6 well and cultured for 24 hrs. Cells were then 
transfected with full NAG-1pCDNA3.1 or mature 
NAG-1pCDNA3.1  or  pCDNA3.1plasmids  using 
FUGENE 6 (Roche, Germany) and cultured in RPMI. 
After 24 hrs, cells were plated1:2 and treated with 
Geneticin (500 µg/ml) for 2 weeks. Stable clones 
for full length and mature forms were collected as 
stable  pool  and  used  for  further  analysis.  mRNA 
expression was analyzed using RT-PCR and specific 
primer pairs targeted to full length or mature form of 
NAG-1 constructs.
Drug resistance and cytotoxicity assay
HT1080 untransfected cells, full NAG-1 stable cells 
and mature NAG-1 stable cells were plated at 10×103 
cells/well in 96 well (six replicate for each group, n=6) 
for 24 hrs. Then cells were treated by indomethacin 
(Hakim  pharmaceutical  co.,  Iran),  celecoxib 
(synthesized in Medicinal Chemistry Lab, Faculty of 
Pharmacy,  Tehran  University  of  Medical  Sciences, 
Iran), tamoxifen (Iran hormone,  Iran) and doxorubicin 
(Ebeve, Austria) in different concentrations for 24 hrs 
and then MTT assay was performed.
To assess the effect of secreted full length and mature 
NAG-1 protein, HT1080 stable cell lines expression 
full length and mature protein were cultured for 
24  hrs.  Untransfected  HT1080  and  MCF7  cells 
were plated at 10×103 cells/well in 96 well for 24 
hrs. Then upper medium of mature NAG-1 stable 
cell line and full NAG-1 stable cell lines were added 
to untransfected HT1080 and MCF7 cell lines. As 
control,  cells  without  changing  the  medium  were 
used. The MTT assay was performed after 24, 48, 72 
hrs incubation.
Statistical analysis
The results were analyzed using one way ANOVA 
followed by Tukey-Kramer post test. The P value less 
than 0.05 (p < 0.05) was considered significant. 
ReSUlTS
Cell proliferation in stable lines
A comparison of the growth curves of HT1080 cells 
stably transfected with full length or mature NAG-1 
with  untransfected  cells  indicate  no  significant 
difference  in  their  proliferation  patterns  (Figure 
2),  although  the  transfected  cell  lines  were  more 
resistance to acidic pH and contact inhibition.
Effect of NAG-1 expression on Drug resistance
Indomethacin (62.5-500 µM) and Celecoxib (100 µM) 
(7), a number of studies have shown that NAG-1 is 
involved in progression of breast, gastric, prostate 
and colorectal carcinomas (8-11). Besides, NAG-1 
serum concentration is elevated in metastatic cancer. 
In  this  regard,  it  has  been  shown  that  NAG-1 
induces invasiveness of human gastric cancer cells 
via multiple pathways including ERK1/2 pathway, 
urokinase  plasminogen  activator  upregulation  and 
MMP pathway (12, 13). NAG-1 over-expression may 
confer resistance of cancer cells to chemotherapy 
and radiotherapy in different cell types (1, 2). 
Therefore, the expression of NAG-1 in cancer cells 
could  affect  the  progression  of  tumor  growth.  In 
addition,  the  secretion  of  full  length  and  mature 
forms  of  NAG-1  can  influence  cells  in  distance 
tissue  and  modulate  their  proliferation.  Thus,  in 
this study the role of full length and mature forms 
of  NAG-1  on  viability  of  HT-1080  and  MCF-7 
cells  were  evaluated.  Furthermore,  the  change  in 
cytotoxicity of celecoxib, indomethacin, tamoxifen 
and doxorubicin in HT-1080 cells stably expressing 
NAG-1 was tested. 
MATeRIAl  AND MeTHOD
Cell lines
Human  cancer  cell  lines  HT1080 ( human 
fibrosarcoma),  MCF7 ( human  breast  carcinoma), 
HCT116 ( human  colorectal  carcinoma)  were 
purchased  from  the  National  Cell  Bank ( Pasture 
institute of Iran, Tehran). Cells were cultured in RPMI 
1640 medium (Biosera, England) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Biosera, 
England) and antibiotics (100 U/ml penicillin and 
100 µg/ml streptomycin; Gibco, USA) and incubated 
in a 37 °C,5% CO2 in humidified atmosphere.
 
Cloning of NAG-1 Full length and mature form
Total RNA was isolated from HCT116 cells using 
Tripure ( Roche,  Germany)    and  2µg  were  used 
for  cDNA  synthesis  using  Revert  Aid  M-MuLV 
reverse  transcriptase ( Fermentas,  Ukraine)  and 
random  hexamer ( Fermentas,  Ukraine).  The 
cDNA  for  NAG-1  full-length  coding  region  was 
amplified  with  primer  pairs  containing  KpnI  or 
EcoRI  restriction  site  (underlined);  Forward: 
5’TCCGGTACCTGCACAGCCATG3’,  Reverse: 
5’GAAGGACCAGGAATTCTCATATGCAG3’. 
The  PCR  product  was  digested  with  EcoRI  and 
KpnI  (Fermentas,  Ukraine)  and  then  ligated 
into  pCDNA3.1.  The  mature  NAG-1  was 
generated  using  PCR  and  following,  Forward: 
5’AGCATGCGAGCGCGCAACGGG3’,and 
Reverse:  5’GCACAGTGGAAGGTACCGGACTG
CTCATA3’  containing  the  C-terminal  112  amino 
acids  of  full  length  protein.  A  start  codon  with 
Kozak  sequence  is  engineered  (underlined)  for 
proper expression of protein. The PCR product was 
cloned into pCR2.1 TOPO (Invitorgen, USA) and 
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Figure 1. The mRNA transcripts of full length and mature form of NAG-1 were analyzed by RT-PCR in HT1080 and stable cell lines of 
HT1080. HCT116 cells were used as positive control.
Figure 4. Effect of  NAG-1 protein on viability of  HT 1080 and MCF-7 cells. 
MCF-7 and HT1080 cells were seeded at 10 ×103 cells/well in 96 well for 24 hrs. The conditioned medium of HT1080 cells stably expressing full 
length and mature form of NAG-1 were collected after 24 hrs and added to MCF-7 (a) and untransfected HT1080 (b) cells. The viability of cells 
incubated with conditioned medium was assessed in 24, 48 and 72 hrs by MTT assay. Data from six replicate (n = 6) are presented as Mean ± SD 
(* p < 0.05, *** p < 0.001, compared to control).
Figure 2. The growth curve of HT1080 cells expressing NAG-1 protein. (a-c) Stable lines and untransfected cells were seeded at 5x104 in 
24well plates and counted at different time using trypan blue dye exclusion. Data from three wells are presented as Mean ± SD (n=3).
Figure 3. Effect of NAG-1 expression on drug cytotoxicity in HT1080 cells. 
HT1080 cells stably expressing full length and mature form NAG-1as well as untransfected HT1080 were seeded at 10×103 cells/well in 96 well 
for 24 hrs. Cells were then treated with different concentration of (a) indomethacin (indo), celecoxib (cele), (b) tamoxifen (tam) and doxorubicin 
(dox) for 24 hrs and MTT assay was performed. Data from six replicate (n=6) are presented as Mean ± SD.
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showed no toxicity on HT1080 cells (Figure 3a). 
Interestingly the HT1080 cells expressing NAG-1 
were  more  viable  than  untransfected  cells.  The 
viability  was  higher  in  cells  expressing  mature 
NAG-1 and at high doses of indomethacin (Figure   
3a)  Doxorubicin  (10-500M)  and  tamoxifen  (25-
50M)  inhibited  HT1080  cell  viability  in  a  dose 
dependent manner (Figure 3b). When Mature and/
or full NAG-1 were expressed, HT1080 cells were 
more resistance to doxorubicine  and tamoxifen at 
low doses (Figure 3b). Similar to COX inhibitors, 
the  viability  was  higher  when  mature  NAG-1  is 
expressed. High doses of doxorubicin and tamoxifen 
did not show any significant difference in transfected 
and untransfected cells.
Effect of full length and mature form on viability of 
HT1080 and MCF-7 cells
Since NAG-1 protein is secreted to the medium, the 
effect of NAG-1 protein on untransfected HT0180 
and MCF-7 cells was investigated  by incubating 
cells  in  conditioned  medium  of  stable  cell  lines 
expressing mature and full length protein. Results 
indicate  that  conditioned  mediums  containing 
NAG-1 protein reduced both cell lines viability by 
20% in 24 hrs (Figure 4). This effect was increased to 
40-50% in 48 hrs for both cell line. The cytotoxicity 
effect was not different for mature and full length 
protein (Figure 4).
DISCUSSION
In this study we have generated stable HT1080 cells 
expressing full length and mature forms of NAG-1 
protein. Results indicate that expression of NAG-1 
does not significantly alter growth curve of HT1080 
cells compared to untransfected cells. On the other 
hand,  addition  of  conditioned  medium  containing 
NAG-1  protein  inhibited  HT1080  and  MCF-7 
proliferation. This effect is in agreement with the 
findings which suggest a tumor suppressor role for 
NAG-1 mature form (2, 5, 6, 9, 11, 14). It has been 
reported that NAG-1 can inhibit proliferation and/or 
induce apoptosis in a p53 dependent manner (5, 6). 
HT1080 and MCF-7 cells are wild type for p53 (15, 
16). Therefore, as it was found, in these cells NAG-1 
can  inhibit  proliferation.  However,  there  was  not 
any significant slow proliferation in stable NAG-1 
expressing cell, suggesting perhaps a compensation 
mechanism in these cells such as upregulation of 
MMP  pathway. A  comparison  of  full  length  and 
mature form indicate similar results for both forms. 
Considering the presence of MT1-MMP in HT1080 
cells that can cleave pro-form of NAG-1 to mature 
form, the full pro-form can be processed to mature 
form and affect the cells. 
It  has  been  shown  that  NAG-1  expression  can 
alter the response to chemotherapeutic agents (17, 
18). Moreover, in colorectal HCT116 cancer cells 
silencing NAG-1 will sensitize tumor to oxaliplatin, 
5-fluorouracil, and SN38 (18). We have evaluated 
the  cytotoxicity  of  tamoxifen  and  doxorubicin  in 
HT1080  cells  expressing  NAG-1  protein.  Results 
showed that at low doses, NAG-1 expression, in full 
length or mature form, increases viability of cells 
treated with tamoxifen or doxorubicin (Figure 3), 
suggesting an increase in drug resistance which is 
blocked at high concentrations. Furthermore, there 
is a reverse correlation between COX-2 and NAG-1 
expression in colorectal tumors(19). When the effect 
of COX inhibitors on viability of HT1080 cells was 
investigated, indomathacin had no cytotoxicity even 
at high doses (500 µM) and celecoxib exerted growth 
inhibition in 200 µM  (Figure 3). Interestingly, NAG-1 
expressing HT1080 cells increased proliferation and 
viability in the presence of indomethacin. This effect 
is dose dependent and reaches to 2 fold elevation 
at 500µM in cells expressing mature form. In the 
presence of celecoxib, a slight increase in viability 
was  observed  in  NAG-1  expressing  cells.  Thus, 
expression of NAG-1 make HT1080 cells susceptible 
to  drug  resistance. Although  the  resistance  is  not 
present at high doses of these drugs, results of this 
study indicate that NAG-1 expression increases risk 
of drug resistance. Furthermore, because of secretory 
nature of NAG-1, release of this protein can affect 
other cells in the body. It has been shown that in early 
stage of cancer, NAG-1 can induce tumor apoptosis, 
and  at  late  stages,  NAG-1  production  will  help 
metastases and tumor progression (9). Furthermore, 
elevated level of NAG-1 in patient with glioblastoma 
has  been  correlated  with  shorter  survival  (20). 
Therefore, NAG-1 expression could induce tumor 
progression and perhaps drug resistance in cancer 
(21). 
CONClUSION
Taken  together,  an  enhanced  drug  resistance  to 
tamoxifen, indomethacin and doxorubicin in HT1080 
cells expressing NAG-1 is reported. Furthermore, 
condition  medium  from  NAG-1  expression  cells 
inhibits  cell  proliferation  in  MCF-7  and  HT1080 
cells. Thus, understanding NAG-1 expression and 
function provides information for effective cancer 
chemotherapy. 
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